{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:07:54Z","timestamp":1767924474601,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Anesthesia"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate transfusion requirements in children receiving aprotinin during craniofacial surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Pediatric craniofacial procedures may involve massive blood loss. Aprotinin may decrease perioperative blood loss and transfusion requirements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (aged 1\u00a0month to 3\u00a0years) who had major reconstructive craniofacial surgery received intraoperative aprotinin (13 patients) or placebo (13 patients). Administered colloids and blood products were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients in the aprotinin and placebo groups had similar mean age, body weight, body surface area, operative time, and length of hospital stay. Mean volumes of total colloids (aprotinin group: 70\u00a0\u00b1\u00a040\u00a0ml; and placebo group: 120\u00a0\u00b1\u00a080\u00a0ml; <jats:italic>P\u00a0\u2264\u00a0<\/jats:italic>0.05) and packed red blood cells (aprotinin group: 380\u00a0\u00b1\u00a090\u00a0ml; and placebo group: 550\u00a0\u00b1\u00a0200\u00a0ml; <jats:italic>P\u00a0\u2264\u00a0<\/jats:italic>0.004) were less in the aprotinin group than in the placebo group. Mean urine output during surgery was greater in the aprotinin group than in the placebo group (320\u00a0\u00b1\u00a0200\u00a0ml vs 150\u00a0\u00b1\u00a070\u00a0ml, respectively; <jats:italic>P\u00a0\u2264\u00a0<\/jats:italic>0.003). Mean blood urea nitrogen and serum creatinine values after surgery were similar between the groups. Complications of aprotinin included anaphylaxis (one patient) and rash (one patient); no deaths occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Aprotinin was associated with decreased packed red blood cell transfusion requirements in children undergoing craniofacial surgery, with no renal toxicity or death. Aprotinin is no longer available for clinical use in the <jats:styled-content style=\"fixed-case\">USA<\/jats:styled-content> because of adverse effects in adults; re\u2010evaluation of aprotinin is warranted for children scheduled to undergo surgery involving potentially high blood loss.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pan.12279","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T13:04:52Z","timestamp":1382101492000},"page":"141-145","source":"Crossref","is-referenced-by-count":9,"title":["Aprotinin and transfusion requirements in pediatric craniofacial surgery"],"prefix":"10.1111","volume":"24","author":[{"given":"Zulfiqar","family":"Ahmed","sequence":"first","affiliation":[{"name":"Anesthesia Associates of Ann Arbor Oakwood Hospital Dearborn MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Stricker","sequence":"additional","affiliation":[{"name":"Department of Anesthesia Children's Hospital of Michigan Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene","family":"Rozzelle","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery Children's Hospital of Michigan Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zestos","sequence":"additional","affiliation":[{"name":"Department of Anesthesia Children's Hospital of Michigan Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(98)00469-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32834ebd59"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199612000-00011"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.BRS.0000090835.45437.7F"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200105150-00012"},{"key":"e_1_2_7_7_1","first-page":"302","article-title":"Use of aprotinin in pediatric lung transplantation","volume":"14","author":"Jaquiss RD","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199012000-00009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91190-1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(98)00964-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802395"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081109"},{"key":"e_1_2_7_13_1","unstructured":"U. S. Food and Drug Administration.2007 Safety alerts for human medical products. Aprotinin injection (marketed as Trasylol). Available at:http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm150815.htm. Accessed 25 January 2013."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1089253209338076"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2009.03227.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000050378"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2003.99.2.0287"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2005.02.035"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197804000-00001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2004.04128.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(98)00333-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707768"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051379"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2011.04.094"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.07.018"}],"container-title":["Pediatric Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpan.12279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pan.12279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:48:00Z","timestamp":1695563280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pan.12279"}},"subtitle":[],"editor":[{"given":"Andrew","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,18]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/pan.12279"],"URL":"https:\/\/doi.org\/10.1111\/pan.12279","archive":["Portico"],"relation":{},"ISSN":["1155-5645","1460-9592"],"issn-type":[{"value":"1155-5645","type":"print"},{"value":"1460-9592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,18]]}}}